Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Amylin”

98 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 98 results

Large-scale testing (Phase 3)Study completedNCT01029886
What this trial is testing

Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes

Who this might be right for
Type 2 Diabetes Mellitus
AstraZeneca 912
Large-scale testing (Phase 3)Study completedNCT00434954
What this trial is testing

Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes

Who this might be right for
Type 2 Diabetes Mellitus
AstraZeneca 494
Not applicableLooking for participantsNCT03481283
What this trial is testing

A Causative Role for Amylin in Diabetic Peripheral Neuropathy

Who this might be right for
Type2 DiabetesPeripheral Neuropathy
Zabeen Mahuwala, MD 40
Testing effectiveness (Phase 2)Study completedNCT01104701
What this trial is testing

Examine the Efficacy, Safety and Tolerability, and Pharmacokinetics of Exenatide Once Monthly Suspension

Who this might be right for
Type 2 Diabetes
AstraZeneca 121
Testing effectiveness (Phase 2)Study completedNCT00819234
What this trial is testing

Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin

Who this might be right for
Obesity
AstraZeneca 274
Post-approval studies (Phase 4)Study completedNCT00870194
What this trial is testing

A Comparison of Adding Exenatide With Switching to Exenatide in Patients With Type 2 Diabetes Experiencing Inadequate Glycemic Control With Sitagliptin Plus Metformin

Who this might be right for
Type 2 Diabetes Mellitus
AstraZeneca 255
Large-scale testing (Phase 3)Study completedNCT00099619
What this trial is testing

Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom Insulin is the Next Appropriate Therapy

Who this might be right for
Type 2 Diabetes Mellitus
AstraZeneca 138
Large-scale testing (Phase 3)Study completedNCT00877890
What this trial is testing

Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)

Who this might be right for
Type 2 Diabetes Mellitus
AstraZeneca 254
Large-scale testing (Phase 3)Study completedNCT00381342
What this trial is testing

Safety and Efficacy of Exenatide as Monotherapy

Who this might be right for
Type 2 Diabetes Mellitus
AstraZeneca 233
Large-scale testing (Phase 3)UnknownNCT01137695
What this trial is testing

Efficacy Study of High Dose Symlin to Treat Type 2 Diabetes Mellitus

Who this might be right for
Type 2 Diabetes Mellitus
Cheryl Rosenfeld, DO 40
Early research (Phase 1)Looking for participantsNCT07010432
What this trial is testing

The Role of the Amylin Analogue Cagrilintide in Bone Metabolism

Who this might be right for
Obesity
Novo Nordisk A/S 144
Testing effectiveness (Phase 2)Study completedNCT00241423
What this trial is testing

Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes

Who this might be right for
Type 2 Diabetes Mellitus
AstraZeneca 30
Large-scale testing (Phase 3)Study completedNCT01144338
What this trial is testing

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Who this might be right for
Type 2 Diabetes Mellitus
AstraZeneca 14,752
Large-scale testing (Phase 3)Study completedNCT00111540
What this trial is testing

Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes

Who this might be right for
Diabetes Mellitus, Type 2
AstraZeneca 456
Not applicableNot Yet RecruitingNCT06692088
What this trial is testing

"Longitudinal Analysis of Amylin Levels in Migraine Patients Undergoing an Anti- CGRP/CGRPr Treatment"

Who this might be right for
High Frequency Episodic Migraine and Chronic Migraine
Fundación Marques de Valdecilla 216
Large-scale testing (Phase 3)Study completedNCT00082381
What this trial is testing

Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin

Who this might be right for
Diabetes Mellitus, Type 2
AstraZeneca 551
Testing effectiveness (Phase 2)Study completedNCT00673387
What this trial is testing

Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects

Who this might be right for
OverweightObesity
AstraZeneca 636
Not applicableNot Yet RecruitingNCT07832032
What this trial is testing

Biological Profiles of Neuropeptides, Neurotrophins and miRNA in Migraine

Who this might be right for
Migraine
Nordlandssykehuset HF 60
Not applicableStudy completedNCT01077323
What this trial is testing

A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Exenatide and Other Antidiabetic Agents

Who this might be right for
Type 2 Diabetes (Treated With Exenatide or Other Oral Antidiabetic Therapies)Healthy Subjects (Treated With no Diabetes Therapies)
AstraZeneca 363,766
Testing effectiveness (Phase 2)Looking for participantsNCT07215559
What this trial is testing

Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

Who this might be right for
ObesityOverweightDiabetes Mellitus, Type 2
Eli Lilly and Company 200
Next Page